跳至主要内容
临床试验/NCT03810287
NCT03810287No Longer Available不适用

The Use Of Domperidone For The Relief Of Refractory Upper Gastrointestinal GI Symptoms

Yale University1 个研究点 分布在 1 个国家开始时间: 2019年1月18日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
No Longer Available
试验地点
1

研究概览

简要总结

To prescribe oral domperidone for patients with upper GI symptoms who have failed or suffered adverse effects from standard medical therapy.

详细描述

The primary objective of this study is to prescribe oral domperidone for patients with upper GI symptoms who have failed or suffered adverse effects from standard medical therapy

研究设计

研究类型
Expanded Access

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males or females who are 18 years of age or older
  • Symptoms or manifestations secondary to Gastro esophageal reflux disease (GERD) (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation that are refractory to standard therapy.

排除标准

  • i. History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded.
  • ii. Clinically significant bradycardia, sinus node dysfunction, or heart block.
  • iii. Prolonged QTc (QTc>450 milliseconds for males, QTc>470 milliseconds for females)
  • iv. Clinically significant electrolyte disorders.
  • Gastrointestinal hemorrhage or obstruction.
  • Presence of a prolactinoma (prolactin-releasing pituitary tumor).
  • Pregnant or breast feedings female.
  • Known allergy to domperidone

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验